Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GenFleet Therapeutics (Shanghai) Inc.

勁方醫藥科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2595)

VOLUNTARY ANNOUNCEMENT
Multiple Innovative Combination Therapies of Oral Pan RAS Inhibitor GFH276 Recently Granted with Clinical Trial Approvals for First-line and Late-line Clinical Studies Addressing Major Tumor Indications in China or Abroad

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the "**Company**" or "**GenFleet**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that, since the third quarter of 2026, multiple innovative combination therapies of the oral Pan RAS inhibitor GFH276 have received clinical trial approvals from the CDE in China or have completed clinical trial notification with the TGA in Australia. Relevant studies address major RAS-mutant indications in first-line and late-line settings, with patients across multiple dose levels enrolled in a certain trial.

Phase Ib/II combination studies of GFH276 approved since the third quarter of 2026			
Regimen	**Treatment Line**	**Study Region**	**Indication**
GFH276 + EGFR antibody, or + chemotherapy	First-line or second-line	China, Australia	RAS-mutant pancreatic cancer and advanced solid tumors
GFH276 + PD-1 antibody ± chemotherapy	First-line	China	RAS-mutant non-squamous non-small cell lung cancer
GFH276 + chemotherapy (± VEGF antibody), or + EGFR antibody	Second-line and beyond	China	RAS-mutant metastatic colorectal cancer

Forward-looking Statements

Specific information in this announcement may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as "predict", "believe", "plan", "forecast", "expect", "will", "may", "should" and other words of similar meanings. Based on the management's current beliefs, plans, estimates and expectations of the Company's operation and market trends subject to changes beyond control, the forward-looking terminology reflects the Company's beliefs, plans, estimates and expectations of future development. Actual outcome in the future may differ significantly from forward-looking words owing to market, policy, and R&D uncertainties, among others. Subject to the above-mentioned uncertainties, the Company makes no expressed or implied guarantee as to the accuracy, completeness or feasibility of this presentation, and you are cautioned not to solely rely on such forward-looking words. Neither the company nor any of its directors, officers, employees, shareholders, agents, related parties, consultants or representatives will be liable to you or any other person for consequences resulting from using this presentation. Investors are advised to exercise due diligence with reference to the company's official disclosures for decision-making.

GLOSSARY OF TECHNICAL TERMS

"CDE"	(Chinese) Center for Drug Evaluation
"EGFR"	epidermal growth factor receptor
"RAS"	rat sarcoma, a family of proteins that are critical regulators of cellular signaling pathways; it primarily includes HRAS, KRAS, and NRAS
"TGA"	(Australian) Therapeutic Goods Administration
"VEGF"	vascular endothelial growth factor

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market GFH276 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, November 4, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang as non-executive director; (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors